Your Article Summary
See Latest ArticlesClinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
British Journal of Haematology, 06/08/09
Sutton R et al. – Study concludes a strong predictive value of minimal residual disease (MRD) kinetics at day 15; should be validated in a larger patient cohort so that earlier detection of risk of relapse can be assessed. In addition, data also provide evidence that additional late MRD monitoring of patients would enable detection of molecular relapse, which, in combination with salvage therapy, may provide the means to further improve survival rates in children with acute lymphoblastic leukaemia (ALL).
Methods- Aim was to evaluate the prognostic significance of MRD at additional treatment phases
- MRD was measured by real-time qPCR on a selected group of 108 pts
- 36 pts with a bone marrow or central nervous system relapse and 72 matched pts in first remission
- MRD was prognostic of outcome at all five treatment phases tested: at day 15, day 35, 4, 12 and 24 mo
- Day 15 was the best early MRD time-point to differentiate between pts with high, intermediate and low risk of relapse
- MRD testing at 12 and particularly at 24 mo, detected molecular relapses in some pts up to 6 mo before clinical relapse
Related Articles
Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F-protocol
Pediatric Blood & Cancer, 10/09/09
Relevance Score: 89%
Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia
British Journal of Haematology, 10/05/09
Relevance Score: 89%
Evaluation of the Effects of Different Transfusion Trigger Levels During the Treatment of Childhood Acute Lymphoblastic Leukemia
Journal of Pediatric Hematology/Oncology, 11/13/09
Relevance Score: 88%
Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia
Leukemia and Lymphoma, 11/06/09
Relevance Score: 88%
Survival After Second Primary Neoplasms of the Brain or Spinal Cord in Survivors of Childhood Cancer: Results From the British Childhood Cancer Survivor Study
Journal of Clinical Oncology, 10/06/09
Relevance Score: 88%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent diagnoses of Hodgkin lymphoma and biclonal myeloma in the bone marrow
Annals of Diagnostic Pathology, 12/04/09
Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience
Acta Haematologica, 12/04/09
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Journal of Clinical Oncology, 12/04/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue
Journal of Neuro-Oncology, 12/04/09
Current Approach to Pediatric Soft Tissue Sarcomas
The Oncologist, 12/03/09
Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia
Hematology, 12/02/09